Multinational investment banking titan Goldman Sachs (GS), which has been trying to recover its foothold in its critical trading units for the last couple of years, reported first-quarter revenue and profit topping analyst estimates. Revenue jumped 25% year-over-year to $10.04 billion, its highest in three years, driven by higher net revenues across all the segments.
In line with the bank’s competitors that reported results earlier this week, earnings applicable to common shareholders surged 26.5% to $2.73 billion, while diluted EPS rose almost 35% to $6.95.
The company, meanwhile, increased its dividend to $0.80 per share from $0.75 per common share, up 6.6%.
Goldman’s investing and lending segment, which includes mortgages to illiquid investments in private start-ups , reported a 43% increase in revenue to $2.1 billion. The bank’s fixed income and equities both had their best quarters in three years as Institutional client securities reported a revenue of $4.4 billion.
In the Investment Banking segment, Goldman posted a revenue of $1.8 billion as its debt capital markets business posted its second best quarterly revenue. The results were driven by leveraged finance and asset-backed activity, and higher net revenues in equity underwriting.
The bank seems to have been improving on its initiatives as is evident in the first quarter results. In the previous quarter, Goldman Sachs posted a net loss, due to the new US tax legislation, but topped consensus estimates as is with this quarter.
In the Investment Banking segment, Goldman posted a revenue of $1.8 billion as its debt capital markets business posted its second best quarterly revenue.
M&A continues to be the linchpin for the company as it recently announced the acquisition of Clarity Money, acquiring about a million customers of the app.
The banking giant’s book value per common share increased by 3.2% during the quarter to $186.73, while annualized return on equity of 15.4% was the highest in over five years.
Goldman Sachs stock jumped 1.5% in the pre-market trading following the earnings announcement.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
What to expect when J.M. Smucker (SJM) reports Q2 2025 earnings results
Shares of The J.M. Smucker Co. (NYSE: SJM) stayed red on Friday. The stock has dropped 6% over the past three months. The branded foods company is slated to report
Earnings Summary: Highlights of BJ’s Wholesale Club’s Q3 2024 results
Department store chain BJ’s Wholesale Club Holdings, Inc. (NYSE: BJ) has reported financial results for the third quarter of 2024, reporting a 3% increase in net sales. Adjusted earnings, on a